Abstract. Proteins involved in the G 1 phase of the cell cycle are aberrantly expressed, sometimes in mutated forms, in human cancers including human hepatocellular carcinoma. Upon attack by a DNA-damaging anticancer drug, a cell arrests at the G 1 phase; this is a safety feature prohibiting entry of DNA-damaged cells into S-phase. p21 WAF1/CIP1 prevents damaged cells from progressing to the next cell cycle. Here, we show that, in response to mitomycin C and doxorubicin, human hepatocellular carcinoma cells generate conflicting signals, mediated by cyclin E and p21 WAF1/CIP1
Introduction
Most anticancer drugs disrupt DNA metabolism and induce DNA damage, and are thus cytotoxic against actively growing tumor cells. The potential molecular targets of such drugs have been intensively investigated with a particular focus on cell cycle and checkpoint control proteins. Cyclins, and the catalytic partners thereof, the cyclin-dependent kinases (CDKs), feature strongly in such work. Aberrant expression of such proteins, particularly cyclin D 1 and cyclin E, that control the G 1 phase of the cell cycle, is found in a variety of human cancers (1, 2) . Overexpression of cyclin D1 and cyclin E accelerates the G 1 -S-phase transition (3), causes chromosomal instability (4) , and alters the sensitivity of cells to anticancer agents (5) . G 1 cyclin action is inhibited upon induction of p21 WAF1/CIP1 , and occurs when an anticancer drug induces DNA damage (6) .
Mitomycin C, an antibiotic produced by Streptomyces caespitosus, is a bioreductive anticancer drug, the reactive forms of which are created via several metabolic steps (7) . Metabolically reactive mitomycin C induces DNA damage via DNA-alkylation, DNA-mono-adduct formation, and intrastrand cross-linking (8, 9) . Such reactions eventually result in antitumor effects in a broad range of human cancers (10) (11) (12) (13) . Doxorubicin is another useful wide-spectrum anticancer drug with a mechanism of action distinct from that of mitomycin C (14) . Doxorubicin efficiently intercalates between DNA bases, and a ternary drug-DNA-topoisomerase II 'cleavable complex' (15, 16 ) is subsequently formed. Such structural changes ultimately inactivate topoisomerase, and excision and rejoining of the damaged region cannot proceed (17) . Thus, although both drugs damage the DNA of cancer cells, mitomycin C and doxorubicin differ in mode of action. However, both mitomycin C-and doxorubicin-induced apoptosis is commonly linked to formation of reactive oxygen species created via redox activation of the drugs (18) (19) (20) (21) . Both mitomycin C and doxorubicin are intra-arterially infused in efforts to increase survival of patients with unresectable advanced hepatocellular carcinoma (22, 23) . However, the side effects associated with the two drugs are severe and the response rate low; these constitute major obstacles to the use of such drugs as whole-body therapeutic regimens (24) . There is therefore relatively little data on responses to such drugs by human hepatocellular carcinoma patients, compared with the information available on responses by patients with other cancers in whom the drugs exert useful effects. In the present study, we characterized the response to mitomycin C and doxorubicin of the human hepatocellular carcinoma cell lines HepG2 and Hep3B, which are of p53 status wild-type and null (25) , respectively. Upon analysis of proteins functioning during the G 1 phase of the cell cycle, it became clear that the two anticancer drugs generated conflicting signals, inducing accumulation of cyclin E prior to that of p21 WAF1/CIP1 in both cell lines. The drug-induced accumulation of cyclin E was both rapid and irrespective of p53 status when the drugs were tested at lethal or sublethal concentrations. This constitutes the first indication that mitomycin C-and doxorubicin-induced accumulation of cyclin E is associated with the G 1 -S-phase transition in human hepatocellular carcinoma cells.
Materials and methods
Cell culture and reagents. The human hepatocellular carcinoma cell lines HepG2 and Hep3B were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in minimum essential medium (MEM) (Gibco, Gaithersburg, MD, USA) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Gibco), at 37˚C under an atmosphere of 95% air and 5% CO 2 . The anticancer drugs used were doxorubicin (catalog no. D1515, Sigma, St. Louis, MI, USA) and mitomycin C (catalog no. 0503, Sigma). The antibodies employed were anti-cyclin E (catalog no. SC-198, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-cyclin D 1 (catalog no. SC-718, Santa Cruz Biotechnology), anti-p21 WAF1/ CIP1 (catalog no. SC-397, Santa Cruz Biotechnology), anti-p53 (catalog no. oP03, millipore, Billerica, mA, USA), and anticdk2 (catalog no. SC-163, Santa Cruz Biotechnology).
Analysis of cytotoxicity, viability, and DNA fragmentation.
The cytotoxicities of mitomycin C and doxorubicin were measured in triplicate using sulforhodamine B dye (catalog no. S2902, Sigma) staining (26) . Asynchronously growing cells (5x10 3 ) were seeded into 96-well plates in 100 µl of medium, and, 24 h later, various concentrations of the drugs were added. three days later, the cells were fixed in 50 µl amounts of cold 50% (v/v) trichloroacetic acid (TCA), washed 5 times with tap water, and next allowed to dry at room temperature. the tCA-fixed cells were stained with 0.1% (w/v) sulforhodamine B solution for 15 min, rinsed with 0.1% (v/v) acetic acid, and next incubated in 10 mM unbuffered Tris (pH 10.5) for 5 min. Cytotoxicity was determined by calculating the absorbance of drug-treated cells relative to that of untreated control cells. The viability of drug-treated cells was evaluated by staining with 0.4% (w/v) trypan blue. The extent of DNA fragmentation was measured using an ELISA kit assessing cell death (catalog no. 11920685001, Roche Diagnostics, GmbH, Germany) according to the manufacturer's instructions.
Western blot analysis. Whole-cell extracts were obtained as lysates in RIPA buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) triton x-100, 1% (w/v) sodium deoxycholate, 0.02 mm phenylmethylsulfonylfluoride, 0.1 mm NaF, 0.01 mM Na 3 VO 4 , and 0.01 mg/ml aprotinin]. Aliquots of the resulting supernatants were separated by SDS-PAGE (12.5%, w/v), transferred to Protran nitrocellulose transfer membranes (Schleicher & Schuell, GmbH, Germany), and probed with specific antibodies. Blots were developed using a secondary antibody (Santa Cruz Biotechnology) and visualized by use of an enhanced chemiluminescence kit (catalog no. SC-2048, Santa Cruz Biotechnology).
Immunoprecipitation and kinase assay. Cyclin E-dependent kinase activity was measured using a specific antibody against cyclin E, as previously described (27) . Briefly, cells were suspended in 500 µl of isotonic lysis buffer [0.2% (v/v) NP-40, 140 mM NaCl, 0.1 mM NaF, 0.01 mM Na 3 VO 4 , 0.01 mg/ml aprotinin, 0.02 mm phenylmethylsulfonylfluoride, and 20 mm Tris-HCl (pH 7.4)]. Whole-cell extracts were precleared using protein G-agarose (catalog no. 11243233001, Roche Diagnostics) and incubated with anti-cyclin E antibody. Immune complexes were collected by absorption onto protein A-or G-agarose beads, and washed with isotonic lysis buffer and kinase assay buffer (10 mM MgCl 2 in 50 mm HEPES, pH 7.4). the final pellets were resuspended in 25 µl amounts of kinase assay buffer containing 1 µg histone H1 (catalog no. 11004875001, Roche Diagnostics), 10 µM ATP, and 5 µCi [γ-
32 P] ATP (3,000 Ci/nmol; NEN, Waltham, MA). The enzymatic reaction was allowed to proceed at 37oC for 15 min and the samples were next subjected to SDS-PAGE (12.5%, w/v). To quantitate kinase activity, proteins were transferred onto nitrocellulose membrane filters and the extent of histone H1 phosphorylation measured by autoradiography.
Cell cycle analysis. Cell cycle status was analyzed by staining of nuclei with propidium iodide and by measuring DNA content using flow cytometry (Becton-Dickinson, mountain View, CA, USA). Cells harvested at various timepoints after drug exposure were adjusted to 1x10 6 cells/ml and stained with 200 µl amounts of pre-cooled propidium iodide solution prior to incubation for 10 min in the dark on ice. The proportion of cells in each phase of the cell cycle was determined by measuring the intensity of nuclear DNA staining by flow cytometry. Chicken erythrocyte nuclei (catalog no. 349523, Becton-Dickinson) were used as a control.
Results

Mitomycin C and doxorubicin cause rapid accumulation of cyclin E in both p53-defective and -proficient cells.
In response to DNA damage induced by anticancer agents, cells arrest at a specific phase of the cell cycle and either repair the damage or enter the cell death pathway. To study the early response of damaged cells, in terms of both cell cycle arrest and death, we monitored expression of the cell cycle activators cyclin D1, cyclin E, and CDK2, and of the cell cycle inhibitor p21
, all of which are active during the G 1 phase of the cycle (28) . Initially, we focused on anticancer drug-induced cell death and estimated the concentrations of drugs affecting cell viability. Lethal concentrations of mitomycin C and doxorubicin, 5 µM and 1 µM, respectively, caused rapid accumulation of cyclin E in both HepG2 and Hep3B cells (Fig. 1 ). the accumulation of cyclin E was evident within 4 h after drug treatment and was sustained to 12-24 h. In terms of induction of cyclin E, the cyclin E-associated kinase was also activated in both HepG2 and Hep3B cells. As expected from consideration of p53 status, HepG2 cells produced p53 protein and the downstream target, p21 WAF1/CIP1 ( Fig. 1A and C) , but p53-null Hep3B cells did not (Fig. 1B and D) . When the kinetics of cyclin E, p53, and p21 WAF1/CIP1 expression by HepG2 cells were analyzed, we found that the accumulation of cyclin E was more rapid than was that of p53 and p21 WAF1/CIP1 ( Fig. 1A and C) . DNA-damaging agents-induced p21 WAF1/CIP1 arrests the cell cycle; this has been well established using a variety of cells and organisms (29) . In contrast to what was observed with cyclin E, cyclin D1 (which is also active in G 1 phase) and the CDK2 as catalytic partner, did not noticeably accumulate in response to genotoxic stress (Fig. 1A-D) . Thus, cyclin E accumulation is an early response, occurring prior to increases in p53 and p21 WAF1/CIP1 levels after exposure to each mitomycin C and doxorubicin. Furthermore, cyclin E accumulation is not associated with p53 status. In . Cyclin E-associated protein kinase activity (CycE-H1K) was assayed in immune complexes precipitated using an anti-cyclin E monoclonal antibody (E and F).
p53-proficient HepG2 cells, mitomycin C or doxorubicin elicit conflicting signals; both activation and inhibition of cell cycle progression are triggered, as indicated by induction of cyclin E and p21
, respectively.
Mitomycin C-or doxorubicin-induced accumulation of cyclin E is associated with the G 1 -S-phase transition.
Since mitomycin C and doxorubicin induced accumulation of cyclin E in both HepG2 and Hep3B cells, and of p21 WAF1/CIP1 in HepG2 cells, we examined whether induction of these two molecules might affect cell cycle transition in response to genotoxic stress. Exposure of actively growing asynchronous cells to either drug resulted in a rapid increase of the proportion of cells in S-phase, accompanied by a concomitant loss of cells in G 1 -phase, for up to 12 h after drug exposure (Fig. 2) , indicating that the G 1 -S-phase transition occurred early after exposure to such agents. Specifically, the cell population in S-phase increased from ~20% to ~40-50% upon exposure to mitomycin C ( Fig. 2A and B) or doxorubicin ( Fig. 2C and D) . The increases in S-phase proportions were mainly attributable to decreases in G 1 population levels, as the 20-30% decrease in the G 1 -phase population was proportional to that of the increase in S-phase cells. A minority of S-phase cells (~5-15%) moved into G 2 /M phase during the same period.
These results indicate that, upon exposure to mitomycin C or doxorubicin, cells in G 1 rapidly progress to S-phase.
When the kinetics of the G 1 -S-phase transition were compared with those of cyclin E or p21 WAF1/CIP1 accumulation in HepG2 cells, it was evident that the phase transition was associated with accumulation of cyclin E rather than the increase in p21
level. The rapid transition from G 1 -to S-phase occurred during the initial 12 h of drug exposure, when only cyclin E accumulation was evident (thus prior to distinct induction of p21 WAF1/CIP1 ) (Figs. 1A and C, and 2A and C). p21 WAF1/CIP1 was strongly induced 24-48 h after drug exposure (Fig. 1A and C) . Such an association of the G 1 -S-phase transition with cyclin E accumulation was also evident in Hep3B cells. In contrast to cessation of the G 1 -S-phase transition evident 12 h after drug exposure in HepG2 cells, the transition continued in Hep3B cells (Fig. 2B and D) , accompanied by cyclin E accumulation, up to 24 h post-treatment (Fig. 1B  and D) . In addition, the increase in the G 2 /M population noted during the first 12 h ceased; G 2 /M cells in fact decreased in number ( Fig. 2B and D) even when cyclin E accumulation continued and p21 WAF1/CIP1 was absent (Fig. 1B and D) . these results indicated that cyclin E accumulation was not associated with the S-G 2 /m-phase transition. these findings indicate that, in response to mitomycin C and doxorubicin, cyclin E accumulation is associated with transition of the G 1 -phase population to the S-phase in human hepatocellular carcinoma cell lines.
Mitomycin C-or doxorubicin-induced accumulation of cyclin E is not associated with DNA fragmentation or cell viability.
Although we found a close correlation between cyclin E accumulation and G 1 -S-phase transition in response to DNA-damaging agents, it was necessary to further investigate whether cyclin E accumulation was also associated with apoptotic cell death. It is known that the genotoxic stress-induced cyclin E fragment p18-cyclin E is associated with such death (30) . Therefore, we compared the kinetics of cyclin E accumulation with those of DNA fragmentation and cell viability. Upon exposure to either mitomycin C or doxorubicin at 5 µM or 1 µM (the concentrations used in the experiments described above), DNA fragmentation was evident in both HepG2 and Hep3B cells (Fig. 3A and B) . However, the kinetics of fragmentation were quite different (mitomycin C, Fig. 3A; doxorubicin, Fig. 3B ), despite the fact that the kinetics of cyclin E accumulation were similar (Fig. 1) . In response to mitomycin C, HepG2 cells rapidly (within 6 h) exhibited DNA fragmentation; this was maximal at 24 h (Fig. 3A) . In contrast, Hep3B cells did not exhibit noticeable DNA fragmentation within 12 h (Fig. 3A) , even though the cyclin E level was increasing (Fig. 1B) . In addition, the extent of mitomycin C-induced DNA fragmentation was significant only 48 h after drug treatment (Fig. 3A) , at which time cyclin E accumulation had ceased (Fig. 1B) . these findings indicate that cyclin E accumulation was not associated with DNA fragmentation. The results obtained after exposure to doxorubicin further support the absence of an association between cyclin E accumulation and DNA fragmentation. In contrast to what was observed for mitomycin C, doxorubicininduced DNA fragmentation in Hep3B cells was much faster than that in HepG2 cells (Fig. 3B ). mitomycin C-or doxorubicin-induced DNA fragmentation caused loss of viability of both HepG2 and Hep3B cells (Fig. 3C and D) . Indeed, DNA fragmentation is typically seen in cells undergoing apoptosis (31) . Thus, cyclin E accumulation is not associated with the DNA fragmentation or viability loss seen upon exposure of human hepatocellular carcinoma cell lines to mitomycin C or doxorubicin.
Mitomycin C-or doxorubicin-induced accumulation of cyclin E occurs at sublethal as well as lethal drug concentrations.
Cell cycle arrest occurs during apoptotic cell death or cell growth cessation (32) . Therefore, we examined the effects of sublethal concentrations of mitomycin C and doxorubicin on cell cycle arrest to determine whether cyclin E affected the G 1 -S transition under such conditions. At mitomycin C levels of <1 µM, distinct loss of HepG2 cell viability was evident, although cell growth was inhibited in a concentration-dependent manner (Fig. 4) ; such drug concentrations were therefore sublethal in HepG2 and Hep3B cells. At such drug concentrations, mitomycin C caused rapid accumulation of cyclin E within 6 h in both cell lines, as was also evident at lethal concentrations ( Fig. 5A and B) . Consistently, an increase of the proportions of cells in S-phase (Figs. 6 and 7D) , and was accompanied by cyclin E accumulation (Fig. 7A) . Unlike the observed rapid cyclin E accumulation, p21 WAF1/CIP1 accumulation at sublethal drug concentrations was delayed, compared with that at lethal drug concentrations, or indeed disappeared, even when cyclin E was accumulating. Specifically, the mitomycin C-induced increase in p21 WAF1/ CIP1 levels evident in HepG2 cells within 12 h of exposure to a lethal drug concentration of 5 µM was also seen 24 h and 48 h after exposure to sublethal drug concentrations of 1 and 0.2 µM, respectively (Fig. 5C) . Also, sublethal concentrations of 0.2 and 0.4 µM doxorubicin led to the delayed appearance of p21 WAF1/CIP1 at 24 and 48 h post-treatment, respectively; accumulation after exposure to a lethal drug concentration of 1 µM was evident 12 h after treatment (Fig. 7C) . Much lower sublethal concentrations that failed to induce p21 WAF1/CIP1 accumulation (Figs. 5C and 7C) could still cause cyclin E accumulation (Figs. 5A and 7A ). Delayed accumulation of p21 WAF1/CIP1 allowed drug-exposed HepG2 cells to escape G 1 -phase arrest, thus continuing the cell cycle transition, until eventually arresting in G 2 /M (Figs. 5E and 7E). Thus, lethal drug concentrations caused cells to arrest at the G 0 /G 1 or G 2 /M phases, but sublethal concentrations of mitomycin C and doxorubicin arrested most cells at G 2 /M (Figs. 5E, 7E, and F) . our present findings thus indicate that the G 1 -S-phase transition induced by sublethal concentrations of anticancer drugs was not affected by p21 WAF1/CIP1 accumulation. Thus, cyclin E impacts the G 1 -S-phase transition of hepatocellular carcinoma cell lines in the presence of sublethal or lethal concentrations of mitomycin C and doxorubicin.
Discussion
Mitomycin C and doxorubicin are used to treat a broad range of human cancers. Drug-DNA complexes are formed via crosslinking of drug with DNA or drug intercalation between DNA bases, thereby causing DNA damage and triggering cellular signaling cascades. To determine early signaling events in cells of cancers that respond poorly to the drugs in vivo, we monitored changes in the levels of proteins involved in G 1 -phase arrest of human hepatocellular carcinoma cells. The response rates of such cells to anticancer drugs are low, and clinical applications are currently limited to intra-arterial chemotherapy.
In the present study, we showed that the two anticancer drugs rapidly induced accumulation of cyclin E (which functions in G 1 phase), but not cyclin D1, in both p53-expressing HepG2 and p53-null Hep3B cells. In HepG2 cells, accumulation of cyclin E was followed by p53-dependent accumulation of p21 , induced by exposure to either mitomycin C or doxorubicin, acted coordinately to control cell cycle transition from G 1 -to S-phase. In fact, cyclin E, but not cyclin D1, is aberrantly overexpressed in human hepatocellular carcinomas (33) . Also, p21 WAF1/CIP1 is often not expressed in such cancers because p53 mutations are often present (34) . The overexpression of cyclin E and p53 mutations often confer radio-and chemo-resistance of cancer cells (35, 36) . Thus, human hepatocellular carcinomas exhibiting both cyclin E overexpression and p53 mutations may not express the complicated and conflicting signals described above in response to such drugs. This may explain why the response rates of such carcinomas to anticancer drugs are low.
The anticancer drug-induced cell cycle transition from G 1 -to S-phase, after attack by DNA-damaging anticancer drugs, differs somewhat from that seen upon growth stimulation of quiescent cells (this requires both cyclin D1 and cyclin E) (37, 38) . Indeed, ectopic overexpression of cyclin D1 or cyclin E shortens the retention time in G 1 , thereby accelerating the G 1 -S-phase transition (39) . Therefore, cyclin E accumulation in response to an anticancer drug is the mechanism by which the progress of damaged cells through the cell cycle, from G 1 -to S-phase, is controlled. Although cyclin D1 and cyclin E play similar roles in the cell cycle, in the sense that ectopic overexpression of either protein accelerates G 1 -S-phase transition, several subtle between-protein differences are apparent. In particular, cyclin D1 overexpression causes the immediate synthesis of hyperphosphorylated pRb; this is not the case when cyclin E is overexpressed (39) . Notably, the effect of cyclin E in asynchronous culture is greater than that of cyclin D1, whereas cyclin D1 has a greater impact when cells are stimulated from quiescence to growth (39) . Addition of growthcompetence agents, such as serum growth factors, to quiescent cells evoke cell cycling via cyclin D1 synthesis followed by that of cyclin E. However, our present results showed that both mitomycin C-and doxorubicin-induced cell cycle acceleration proceeded via accumulation of cyclin E but not cyclin D1. Thus, upon addition of either mitomycin or doxorubicin to human hepatocellular carcinoma cells, cyclin E accumulation triggered rapid cell cycle transition. Although we showed that anticancer drug-induced accumulation of cyclin E was clearly associated with the G 1 -S-phase transition, we could not exclude the possibility that cyclin E accumulation was also linked to apoptosis. Indeed, genotoxic stress induces both cyclin E and an associated CDK2 activity (40) , and cyclin E induction is linked to apoptosis (41) . However, the fact that sublethal concentrations of mitomycin C and doxorubicin also caused accumulation of cyclin E eliminated the possibility of an association between such accumulation and apoptosis. Furthermore, the onset of cyclin E accumulation and DNA fragmentation differed when the two drugs were tested in the same cell line and between cell lines exposed to the same drug. Thus, mitomycin C-or doxorubicin-induced cyclin E accumulation is associated with the G 1 -S-phase transition. However, the 18-kDa fragment of cyclin E, p18-cyclin E, plays a role in apoptosis via interaction with Ku70 (42). p18-cyclin E is derived by proteolytic cleavage of full-length cyclin E during apoptosis. This form of cyclin E cannot bind to the catalytic subunit CDK2, and is thus not involved in cell cycle progression (30) . Therefore, genotoxic stress-induced fulllength cyclin E and p18-cyclin E differ in terms of biological activity; full-length cyclin E affects the G 1 -S-phase transition, but p18-cyclin E influences apoptosis.
Upon exposure to drugs of p53-proficient HepG2 cells, p21
WAF1/CIP1 accumulation, following the increase in cyclin E levels, ultimately caused cell cycle arrest. Unlike what was noted when cyclin E accumulation occurred rapidly, sublethal levels of mitomycin C and doxorubicin (irrespective of concentration) delayed p21
WAF1/CIP1 accumulation, permitting the cell cycle to continue; most cells ultimately arrested in G 2 /M. In fact, p21 WAF1/ CIP1 has a role in the G 1 checkpoint of the cell cycle (43) . A deficiency of p21 WAF1/CIP1 causes loss of the G 1 checkpoint (44). Thus, HepG2 cells expressing p21 WAF1/CIP1 arrest at either G 1 or G 2 /M depending on the concentration of anticancer drug present.
In our present work, we precisely dissected the kinetics of accumulation of both a cell cycle accelerator, cyclin E, and a cell cycle-inhibitory protein, p21 WAF1/CIP1 . The data indicate that mitomycin C-and doxorubicin-induced cyclin E accumulation is coordinated with p21 WAF1/CIP1 expression to control the G 1 -S-phase transition in human hepatocellular carcinoma cells. However, it is necessary to further investigate why cancer cells, including those of hepatocellular carcinomas, generate conflicting signals, both accelerating and inhibiting progression of the cell cycle.
